Fifty organizations, including the American Society of Clinical Oncology, have expressed their confidence in Robert Califf, MD, to lead the FDA.
In a joint letter to the Senate Committee on Health, Education, Labor, and Pensions, the American Society of Clinical Oncology and 50 other national and local organizations, have backed the nomination of Robert Califf, MD, as Commissioner of the FDA. Dr Califf, if approved, will take over the reigns of the regulatory body from temporary chief, Stephen Ostroff, MD. Dr Ostroff was filling-in for Margaret Hamburg, MD, who stepped down in February this year.
Dr Califf has spent most of his career in academia, with more than 30 years as a prominent cardiologist and medical researcher at Duke University. However, he has some experience with the FDA, having served on the agency's Cardiorenal Advisory Panel from 1996 to 2000 and its Science Board Working Group from 2007 to 2008.
In the letter, the organizations declare their confidence in Dr Califf, stating, "We believe that with Dr Califf's diverse background, and his exemplary knowledge of clinical and translational medicine, he will continue to improve the FDA's drug approval process while ensuring that patients are receiving the safest and most effective treatments as quickly as possible. We urge his immediate confirmation."
Read the letter.
Contributor: For Complex Cases, Continuity in Acute Care Is Necessary
April 23rd 2025For patients with complex needs and social challenges like unstable housing, the hospital has become their de facto medical home—yet each visit is a fragmented restart, without continuity, context, or a clear path forward.
Read More
Higher Weight-Adjusted Waist Index Tied to Greater Mortality Risk in Patients With Osteoarthritis
April 23rd 2025Researchers consider the weight-adjusted waist index a more precise predictor of mortality risk in patients with osteoarthritis than traditional obesity measures, like body mass index.
Read More